scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1035158601 |
P356 | DOI | 10.1023/A:1006195815320 |
P698 | PubMed publication ID | 10360605 |
P2093 | author name string | S Murthy | |
P Elson | |||
D McLain | |||
R Bukowski | |||
G T Budd | |||
D Peereboom | |||
K Rajagopalan | |||
T Olencki | |||
P2860 | cites work | Cancer statistics, 1998. | Q34065873 |
Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial | Q34683968 | ||
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer | Q41072693 | ||
Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial | Q41273703 | ||
Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer | Q43739019 | ||
Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer | Q46260324 | ||
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. | Q53622998 | ||
The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate | Q67779831 | ||
Circadian variation of fluoropyrimidine catabolic enzymes in rat liver: possible relevance to 5-fluorodeoxyuridine chemotherapy | Q68297244 | ||
Determination of the therapeutic index of floxuridine by its circadian infusion pattern | Q68410401 | ||
Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infus | Q68689282 | ||
Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma | Q70058111 | ||
Weekly doxorubicin in endocrine-refractory carcinoma of the prostate | Q71186859 | ||
Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer | Q72078080 | ||
Phase I study of continuous venous infusion of floxuridine (5-FUDR) chemotherapy | Q72791795 | ||
A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study | Q72910588 | ||
THE PHYSIOLOGIC DISPOSITION OF 5-FLUOROURACIL AND 5-FLUORO-2'-DEOXYURIDINE IN MAN | Q76959399 | ||
P433 | issue | 3 | |
P921 | main subject | prostate cancer | Q181257 |
floxuridine | Q5462356 | ||
phase II clinical trial | Q42824440 | ||
P304 | page(s) | 255-258 | |
P577 | publication date | 1998-01-01 | |
P1433 | published in | Investigational New Drugs | Q2312231 |
P1476 | title | Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer | |
P478 | volume | 16 |
Q34155429 | Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress? |
Q35145701 | Current strategies in the management of hormone refractory prostate cancer |
Q28279056 | Systematic review of agents for the management of gastrointestinal mucositis in cancer patients |
Q28077467 | WOMEN IN CANCER THEMATIC REVIEW: Circadian rhythmicity and the influence of 'clock' genes on prostate cancer |
Search more.